Pfizer has summarized the interim results of the EPIC-HR phase 2/3 clinical trial of PAXLOVID, an oral antiviral drug for COVID-19. Use of PAXLOVID reduced the risk of hospitalization or death from COVID-19 by 89% compared to patients with placebo. The company plans to submit data to the FDA soon for approval for emergency use of the drug.
Pfizer has summarized the interim results of the EPIC-HR phase 2/3 clinical trial of PAXLOVID, an oral antiviral drug for COVID-19. Use of PAXLOVID reduced the risk of hospitalization or death from COVID-19 by 89% compared to patients with placebo. The company plans to submit data to the FDA soon for approval for emergency use of the drug. 
investors.pfizer.com
English (US) 